Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $108.4 million.

  • Corcept Therapeutics' Accumulated Expenses rose 3647.31% to $108.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.4 million, marking a year-over-year increase of 3647.31%. This contributed to the annual value of $90.7 million for FY2024, which is 7567.99% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Accumulated Expenses of $108.4 million as of Q3 2025, which was up 3647.31% from $91.1 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Accumulated Expenses registered a high of $108.4 million during Q3 2025, and its lowest value of $18.0 million during Q1 2021.
  • For the 5-year period, Corcept Therapeutics' Accumulated Expenses averaged around $52.6 million, with its median value being $51.6 million (2023).
  • In the last 5 years, Corcept Therapeutics' Accumulated Expenses plummeted by 812.15% in 2021 and then surged by 13675.03% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Accumulated Expenses (Quarter) stood at $27.7 million in 2021, then rose by 11.33% to $30.8 million in 2022, then skyrocketed by 67.63% to $51.6 million in 2023, then surged by 75.68% to $90.7 million in 2024, then grew by 19.57% to $108.4 million in 2025.
  • Its last three reported values are $108.4 million in Q3 2025, $91.1 million for Q2 2025, and $88.9 million during Q1 2025.